ClinicalTrials.gg
CompletedNCT02696798COAST-WUpdated Jun 17, 2020Results posted

A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis

A Phase 3 interventional study of Ixekizumab and Placebo in Spondyloarthritis, sponsored by Eli Lilly and Company. Completed at 99 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-17.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
316
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Spondylarthritis with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Spondylarthritis · United States.

Enrollment
8th of 14
316 · median 329
Started
2016
with 2 others
Phase 3
7 of 27
none open now
Registered
14th of 27
by date
Lead sponsor
3 of 27
Eli Lilly and Company

Among the 27 studies in Spondylarthritis with a site in United States, this one is the 8th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2016, is one of 7 in phase 3, and was the 14th registered.

Spondylarthritis

203 studies on the registry are indexed under Spondylarthritis; 52 are open to participants now.

Browse Spondylarthritis studies →

Open to participants now

6 of the 27 studies in Spondylarthritis with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 37 Spondylarthritis studies recruiting now, 20 (54%) set no upper age limit and 9 (24%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Spondylarthritis with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in tumor necrosis factor (TNF) inhibitor-experienced participants with radiographic axial spondyloarthritis (rad-axSpA).

03

Conditions studied

  • Spondyloarthritis

Keywords

  • Ankylosing Spondylitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are ambulatory.
  • Have an established diagnosis of radiographic axial spondyloarthritis (rad-xSpA) with sacroiliitis defined radiographically according to the modified New York criteria.
  • Participants have a history of back pain ≥3 months with age at onset \<45 years.
  • Have had prior treatment with at least 1 and not more than 2 TNF inhibitors.
  • Must have had an inadequate response to 2 or more NSAIDs at the therapeutic dose range for a total duration of at least 4 weeks OR have a history of intolerance to NSAIDs.
  • Have a history of prior therapy for axSpa for at least 12 weeks prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Have total ankylosis of the spine.
  • Have never taken a TNF inhibitor medication or have taken more than 2.
  • Have recently received a within 12 weeks or have had a vaccination with Bacillus Calmette-Guerin (BCG) within the past year.
  • Have an ongoing or serious infection within the last 12 weeks or evidence of active tuberculosis.
  • Have a compromised immune system.
  • Have any other serious and/or uncontrolled diseases.
  • Have either a current diagnosis or a recent history of malignant disease.
  • Have had major surgery within 8 weeks of baseline, or will require surgery during the study.
  • Are pregnant or breastfeeding.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
316 participants (actual)

Study arms

  • Experimental
    Q2W Ixekizumab

    Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14. Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52.

    Drug: Ixekizumab

  • Experimental
    Q4W Ixekizumab

    Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14. Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52.

    Drug: Ixekizumab

  • Placebo comparator
    Placebo

    Double Blind Period: Placebo given SC Q2W to week 14. Extended Treatment Period: Starting dose of 160 mg ixekizumab given SC at week 16 followed by 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52.

    Drug: Ixekizumab · Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY2439821

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response

    ASAS40 is defined as improvement from baseline of greater than or equal to (\>=) 40 % and absolute improvement from baseline of at least 2 units (range of 0 to 10) in at least 3 of the following 4 domains without any worsening in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Achieving an ASAS20 Response

    ASAS20 response is defined as a ≥20% improvement and an absolute improvement from baseline of ≥1 units (range 0 to 10) in ≥3 of 4 domains, and no worsening of ≥20% and ≥1 unit (range 0 to 10) in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).

    Time frame: Week 16

  2. Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)

    ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness and 5. CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Least Square (LS) mean was determined by mixed-model repeated measures (MMRM) with treatment, geographic region, baseline CRP status, number of prior tumor necrosis factor inhibitor (TNFi), baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  3. Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response

    The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis (rad-axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. BASDAI50 represents an improvement of ≥50% of the BASDAI score from baseline.

    Time frame: Week 16

  4. Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

    The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis (rad-axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. LSmean was determined by MMRM with factors for treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  5. Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)

    The BASFI is a participant-reported assessment that establishes a participant's functional baseline and subsequent response to treatment. The BASFI is composed with 10 questions to assess the disease severity, including the first 8 questions regarding to functional anatomy related activities and the remaining 2 questions related to daily activities of AS participants. Participants respond to each question using an NRS scale (range 0 to 10). The BASFI score is the average of the 10 responses and has a possible minimum value of 0 and a possible maximum value of 10, with a higher score indicating worse function. LS mean was determined by MMRM with factors for treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  6. Percentage of Participants Achieving ASDAS Inactive Disease

    ASDAS is a composite index to assess disease activity in AS. ASDAS Inactive Disease is defined as a score of \<1.3. The parameters used for the ASDAS (with CRP as acute phase reactant) are 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness and 5. CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.

    Time frame: Week 16

  7. Percentage of Participants Achieving ASDAS <2.1

    ASDAS is a composite index to assess disease activity in AS. ASDAS \<2.1 defines moderate disease activity. The parameters used for the ASDAS (with CRP as acute phase reactant) are 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness and 5. CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.

    Time frame: Week 16

  8. Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores

    The SF-36 is a 36-item participant administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The 2 overarching domains of mental well- being and physical well-being are captured by the Mental Component Summary and Physical Component Summary scores. T-scores are used for analysis. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LSmean was determined by MMRM with factors for treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  9. Change From Baseline in ASAS Health Index (ASAS HI)

    The ASAS Health Index (ASAS HI) is a disease specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17 item instrument has scores ranging from 0 (good Health) to 17 (poor Health). Each item consists of 1 question that the patient needs to respond to with either "I agree" (score 1) or "I do not agree (score 0)." A score of "1" is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  10. Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Ankylosing Spondylitis Spinal Magnetic Resonance Imaging [ASSpiMRI] - Berlin Score)

    The study used MRI with fat-saturating techniques such as short tau inversion recovery (STIR) to look for the presence of bone marrow edema. The Berlin modification of Ankylosing Spondylitis spine MRI score for activity (ASspiMRI) scoring technique assesses inflammation in each of the 23 disco-vertebral units (DVU) of the spine (from C2 to S1), capturing bone marrow edema. Scores for each DVU range from 0-3 (0=normal; 1=minor bone marrow edema \[less than or equal to 25% of DVU; 3=severe bone marrow edema (more that 50% of DVU)\]. The composite score ranges from 0 to 69, with higher scores reflecting worse disease.LS mean was determined by analysis of covariance (ANCOVA) with treatment, geographic region, baseline CRP status, number of prior TNF inhibitors used and baseline value as fixed factors.

    Time frame: Baseline, Week 16

  11. Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score)

    MRI score of spine was assessed using SPARCC method. All 23 disco-vertebral units (DVU) of the spine (from C2 to S1) were scored for bone marrow edema. A single DVU has 18 scoring units, and each has score of 0 or 1, bringing the maximum total score to 414, the sum ranges from 0 to 414 with higher scores reflecting worse disease. Scoring was performed by central readers. LS mean was determined by ANCOVA with factors for treatment, geographic region, baseline CRP status, number of prior TNF inhibitors used and baseline value.

    Time frame: Baseline, Week 16

  12. Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)

    High sensitivity CRP is the measure of acute phase reactant. It was measured with a high sensitivity assay at the central laboratory to help assess the effect of ixekizumab on disease activity. High sensitivity CRP is a sensitive laboratory assay for serum levels of C-Reactive Protein, which is a biomarker of inflammation. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  13. Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)

    BASMI is a combined index comprising of 5 clinical measurements of spinal mobility in patients with radiographic axial spondyloarthritis (rad-axSpA). 1. Lateral Spinal Flexion 2. Tragus-to-wall distance 3. Lumbar Flexion (modified Schober) 4. Maximal intermalleolar distance and 5. Cervical rotation. The BASMI linear result is the average of the 5 assessments and ranges from 0 to 10. The higher the BASMI score the more severe the patient's limitation of movement due to their AS. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  14. Change From Baseline in Chest Expansion

    Chest expansion is the difference, in centimeter (cm), between the circumference of the chest in maximal inspiration and maximal expiration. While patients have their hands resting on or behind the head, the assessor will measure the chest encircled length by centimeter (cm) at the fourth intercostal level anteriorly. Two tries were recorded. The better measurement (larger difference) of 2 tries (in centimeters) was used for analyses. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  15. Change From Baseline in Occiput to Wall Distance

    The participant is to make a maximum effort to touch the head against the wall when standing with heels and back against the wall (occiput). Then the distance from occiput to wall is measured. Two tries will be recorded. The better (smaller) measurement of 2 tries (in centimeters) will be used for analyses. LS mean was determined by MMRM with factors for treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  16. Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)

    The MASES is an index used to measure the severity of enthesitis. The MASES assesses 13 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include costochondral 1 (right/left), costochondral 7 (right/left), spinal iliaca anterior superior (right/left), crista iliaca (right/left), spina iliaca posterior (right/left), processus spinosus L5, and Achilles tendon proximal insertion (right/left). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  17. Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Score

    The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  18. Change From Baseline in Severity of Peripheral Arthritis by Tender Joint Count (TJC) Scores

    The number of tender and painful joints was determined by examination of 46 joints (23 joints on each side of the body). The 46 joints were assessed and classified as tender or not tender. Sum of all joints checked to be tender/painful divided by number of evaluable joints which was multiplied by 46 to obtain TJC score. The scores ranges from 0 (no tender/painful joints) to 46 (all joints tender/painful). LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction.

    Time frame: Baseline, Week 16

  19. Change From Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC) Scores

    The number of swollen joints was determined by examination of 44 joints (22 joints on each side of the body). The 44 joints were assessed and classified as swollen or not swollen. Sum of all joints checked to be swollen divided by number of evaluable joints which was multiplied by 44 to obtain SJC score. The SJC score ranges from 0 (no swollen joints) to 44 (all joints swollen). LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction.

    Time frame: Baseline, Week 16

  20. Percentage of Participants With Anterior Uveitis

    Anterior uveitis is an inflammation of the middle layer of the eye. which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.

    Time frame: Week 16

  21. Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score

    The fatigue severity NRS is a participant administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine". Participants rate their fatigue (feeling tired or worn out) by circling the 1 number that describes their worst level of fatigue during the previous 24 hours. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  22. Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)

    The Jenkins Sleep Evaluation Questionnaire (JSEQ) is a 4 item scale designed to estimate sleep problems in clinical research. The JSEQ assesses the frequency of sleep disturbance in 4 categories: 1) trouble falling asleep, 2) waking up several times during the night, 3) having trouble staying asleep (including waking up far too early), and 4) waking up after the usual amount of sleep feeling tired and worn out. Patients report the numbers of days they experience each of these problems in the past month on a 6 point Likert Scale ranging from 0 = "no days" to 5 = "22-30 days. The total JSEQ score ranges from 0 to 20, with higher scores indicating greater sleep disturbance. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 16

  23. Change From Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores

    The WPAI-SpA consists of 6 questions to determine employment status, hours missed from work because of SpA, hours missed from work for other reasons, hours actually worked, the degree to which SpA affected work productivity while at work, and the degree to which SpA affected activities outside of work. The WPAI-SpA has been validated in the rad-axSpA patient population. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. The computed percentage range for each sub-scale was from 0-100, with higher scores indicating greater impairment and less productivity. LS mean was determined by ANCOVA with treatment, geographic region, baseline CRP status, number of prior TNFi and baseline value as fixed factors.

    Time frame: Baseline, Week 16

  24. Change From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score

    ASAS-NSAID score is used to present the NSAID intake by considering the type of NSAID, the total dose, \& the number of days taking NSAID during a period of interest (PI). For NSAID equivalent scoring system, range is from 0 to 100, higher the score greated the NSAID intake. ASAS-NSAID score= (equivalent NSAID score) x (days of intake during PI) x (days per week)/(PI in days).

    Time frame: Baseline, Week 52

  25. Percentage of Participants With Anti-Ixekizumab Antibodies

    A treatment emergent - antidrug antibody (TE-ADA) positive patient is defined as: a) a patient with a \>= 4-fold increase over a positive baseline antibody titer; or b) for a negative baseline titer, a patient with an increase from the baseline to a level of \>= 1:10. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.

    Time frame: Week 16

  26. Pharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss)

    Pharmacokinetics (PK): Steady-state trough serum concentration of Ixekizumab at week 16.

    Time frame: Week 16

07

Results

Posted Oct 30, 2019

Participant flow

Blinded Treatment Dosing Period (Week 0 to Week 16), Extended Treatment Period (Week 16 to Week 52) followed by post-treatment follow-up period occurring from last treatment visit (week 52), or Early Termination Visit (ETV) up to a minimum of 12 weeks following that visit.

Blinded Treatment Dosing Period
Participant flow — Blinded Treatment Dosing Period
MilestonePBO/IXEIXE80Q4W/IXE80Q4WIXE80Q2W/IXE80Q2W
Started10411498
Completed939990
Not completed11158
Withdrew: Adverse event292
Withdrew: Death001
Withdrew: Lack of efficacy211
Withdrew: Lost to follow-up010
Withdrew: Physician decision010
Withdrew: Withdrawal by subject734
Extended Treatment Period
Participant flow — Extended Treatment Period
MilestonePBO/IXEIXE80Q4W/IXE80Q4WIXE80Q2W/IXE80Q2W
Started939890
Completed818980
Not completed12910
Withdrew: Adverse event145
Withdrew: Lack of efficacy722
Withdrew: Lost to follow-up100
Withdrew: Physician decision010
Withdrew: Withdrawal by subject323
Post-treatment Follow-up Period
Participant flow — Post-treatment Follow-up Period
MilestonePBO/IXEIXE80Q4W/IXE80Q4WIXE80Q2W/IXE80Q2W
Started53422
Completed083
Not completed52619
Withdrew: Adverse event2126
Withdrew: Lost to follow-up011
Withdrew: Lack of efficacy120
Withdrew: Withdrawal by subject2812
Withdrew: Physician decision020
Withdrew: No progressive improvement010

Outcome measures

PrimaryPercentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response

ASAS40 is defined as improvement from baseline of greater than or equal to (\>=) 40 % and absolute improvement from baseline of at least 2 units (range of 0 to 10) in at least 3 of the following 4 domains without any worsening in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response
Percentage of participantsPlacebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response12.525.430.6
Statistical analysis
  • Placebo vs 80 mg Q4W Ixekizumab · Regression, Logistic · p = 0.017 · Odds ratio (or): 2.41 · 95% CI 1.17 to 4.95
  • Placebo vs 80 mg Q2W Ixekizumab · Regression, Logistic · p = 0.003 · Odds ratio (or): 3.06 · 95% CI 1.48 to 6.33
SecondaryPercentage of Participants Achieving an ASAS20 Response

ASAS20 response is defined as a ≥20% improvement and an absolute improvement from baseline of ≥1 units (range 0 to 10) in ≥3 of 4 domains, and no worsening of ≥20% and ≥1 unit (range 0 to 10) in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving an ASAS20 Response
Percentage of ParticipantsPlacebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Percentage of Participants Achieving an ASAS20 Response29.848.246.9
Statistical analysis
  • Placebo vs 80 mg Q4W Ixekizumab · Regression, Logistic · p = 0.006 · Odds ratio (or): 2.20 · 95% CI 1.26 to 3.84
  • Placebo vs 80 mg Q2W Ixekizumab · Regression, Logistic · p = 0.013 · Odds ratio (or): 2.08 · 95% CI 1.16 to 3.73
SecondaryChange From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)

ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness and 5. CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Least Square (LS) mean was determined by mixed-model repeated measures (MMRM) with treatment, geographic region, baseline CRP status, number of prior tumor necrosis factor inhibitor (TNFi), baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)
Units on a scalePlacebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)-0.11 ± 0.099-1.16 ± 0.094-1.13 ± 0.103
Statistical analysis
  • Placebo vs 80 mg Q4W Ixekizumab · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -1.05 · 95% CI -1.32 to -0.79
  • Placebo vs 80 mg Q2W Ixekizumab · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -1.03 · 95% CI -1.30 to -0.75
SecondaryPercentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response

The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis (rad-axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. BASDAI50 represents an improvement of ≥50% of the BASDAI score from baseline.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response
Percentage of ParticipantsPlacebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response9.621.923.5
Statistical analysis
  • Placebo vs 80 mg Q4W Ixekizumab · Regression, Logistic · p = 0.015 · Odds ratio (or): 2.65 · 95% CI 1.21 to 5.84
  • Placebo vs 80 mg Q2W Ixekizumab · Regression, Logistic · p = 0.010 · Odds ratio (or): 2.90 · 95% CI 1.29 to 6.49
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis (rad-axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. LSmean was determined by MMRM with factors for treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
Units on a scalePlacebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)-0.92 ± 0.212-2.17 ± 0.202-2.09 ± 0.221
Statistical analysis
  • Placebo vs 80 mg Q4W Ixekizumab · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -1.24 · 95% CI -1.81 to -0.67
  • Placebo vs 80 mg Q2W Ixekizumab · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -1.16 · 95% CI -1.76 to -0.57
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)

The BASFI is a participant-reported assessment that establishes a participant's functional baseline and subsequent response to treatment. The BASFI is composed with 10 questions to assess the disease severity, including the first 8 questions regarding to functional anatomy related activities and the remaining 2 questions related to daily activities of AS participants. Participants respond to each question using an NRS scale (range 0 to 10). The BASFI score is the average of the 10 responses and has a possible minimum value of 0 and a possible maximum value of 10, with a higher score indicating worse function. LS mean was determined by MMRM with factors for treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)
Units on a scalePlacebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)-0.64 ± 0.215-1.69 ± 0.205-1.92 ± 0.225
Statistical analysis
  • Placebo vs 80 mg Q4W Ixekizumab · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -1.05 · 95% CI -1.63 to -0.47
  • Placebo vs 80 mg Q2W Ixekizumab · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -1.28 · 95% CI -1.89 to -0.68
SecondaryPercentage of Participants Achieving ASDAS Inactive Disease

ASDAS is a composite index to assess disease activity in AS. ASDAS Inactive Disease is defined as a score of \<1.3. The parameters used for the ASDAS (with CRP as acute phase reactant) are 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness and 5. CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving ASDAS Inactive Disease
Percentage of ParticipantsPlacebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Percentage of Participants Achieving ASDAS Inactive Disease1.03.55.1
Statistical analysis
  • Placebo vs 80 mg Q4W Ixekizumab · Regression, Logistic · p = 0.242 · Odds ratio (or): 3.73 · 95% CI 0.41 to 33.98
  • Placebo vs 80 mg Q2W Ixekizumab · Regression, Logistic · p = 0.127 · Odds ratio (or): 5.42 · 95% CI 0.62 to 47.54
SecondaryPercentage of Participants Achieving ASDAS <2.1

ASDAS is a composite index to assess disease activity in AS. ASDAS \<2.1 defines moderate disease activity. The parameters used for the ASDAS (with CRP as acute phase reactant) are 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness and 5. CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving ASDAS <2.1
Percentage of ParticipantsPlacebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Percentage of Participants Achieving ASDAS <2.14.817.516.3
Statistical analysis
  • Placebo vs 80 mg Q4W Ixekizumab · Regression, Logistic · p = 0.006 · Odds ratio (or): 4.22 · 95% CI 1.50 to 11.86
  • Placebo vs 80 mg Q2W Ixekizumab · Regression, Logistic · p = 0.006 · Odds ratio (or): 4.52 · 95% CI 1.55 to 13.18
SecondaryChange From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores

The SF-36 is a 36-item participant administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The 2 overarching domains of mental well- being and physical well-being are captured by the Mental Component Summary and Physical Component Summary scores. T-scores are used for analysis. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LSmean was determined by MMRM with factors for treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores
Units on a scalePlacebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
SF-36 MCS2.7410 ± 0.94523.5099 ± 0.90743.6514 ± 0.9921
SF-36 PCS1.3638 ± 0.81466.5785 ± 0.77636.1223 ± 0.8465
Statistical analysis
  • Placebo vs 80 mg Q4W Ixekizumab · Mixed Models Analysis · p = 0.550 · Ls mean difference (final values): 0.7689 · 95% CI -1.7629 to 3.3007
  • Placebo vs 80 mg Q2W Ixekizumab · Mixed Models Analysis · p = 0.495 · Ls mean difference (final values): 0.9104 · 95% CI -1.7151 to 3.5360
  • Placebo vs 80 mg Q4W Ixekizumab · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): 5.2147 · 95% CI 3.0204 to 7.4090
  • Placebo vs 80 mg Q2W Ixekizumab · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): 4.7585 · 95% CI 2.4940 to 7.0230
SecondaryChange From Baseline in ASAS Health Index (ASAS HI)

The ASAS Health Index (ASAS HI) is a disease specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17 item instrument has scores ranging from 0 (good Health) to 17 (poor Health). Each item consists of 1 question that the patient needs to respond to with either "I agree" (score 1) or "I do not agree (score 0)." A score of "1" is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in ASAS Health Index (ASAS HI)
Units on a scalePlacebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Change From Baseline in ASAS Health Index (ASAS HI)-0.89 ± 0.338-1.92 ± 0.322-1.58 ± 0.352
Statistical analysis
  • Placebo vs 80 mg Q4W Ixekizumab · Mixed Models Analysis · p = 0.026 · Ls mean difference (final values): -1.03 · 95% CI -1.94 to -0.13
  • Placebo vs 80 mg Q2W Ixekizumab · Mixed Models Analysis · p = 0.149 · Ls mean difference (final values): -0.69 · 95% CI -1.63 to 0.25
SecondaryChange From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Ankylosing Spondylitis Spinal Magnetic Resonance Imaging [ASSpiMRI] - Berlin Score)

The study used MRI with fat-saturating techniques such as short tau inversion recovery (STIR) to look for the presence of bone marrow edema. The Berlin modification of Ankylosing Spondylitis spine MRI score for activity (ASspiMRI) scoring technique assesses inflammation in each of the 23 disco-vertebral units (DVU) of the spine (from C2 to S1), capturing bone marrow edema. Scores for each DVU range from 0-3 (0=normal; 1=minor bone marrow edema \[less than or equal to 25% of DVU; 3=severe bone marrow edema (more that 50% of DVU)\]. The composite score ranges from 0 to 69, with higher scores reflecting worse disease.LS mean was determined by analysis of covariance (ANCOVA) with treatment, geographic region, baseline CRP status, number of prior TNF inhibitors used and baseline value as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Ankylosing Spondylitis Spinal Magnetic Resonance Imaging [ASSpiMRI] - Berlin Score)
Units on a scalePlacebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Ankylosing Spondylitis Spinal Magnetic Resonance Imaging [ASSpiMRI] - Berlin Score)1.03 ± 0.379-0.92 ± 0.373-1.14 ± 0.414
Statistical analysis
  • Placebo vs 80 mg Q4W Ixekizumab · ANCOVA · p = <0.001 · Ls mean difference (final values): -1.95 · 95% CI -3.0 to -0.9
  • Placebo vs 80 mg Q2W Ixekizumab · ANCOVA · p = <0.001 · Ls mean difference (final values): -2.17 · 95% CI -3.2 to -1.1
SecondaryChange From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score)

MRI score of spine was assessed using SPARCC method. All 23 disco-vertebral units (DVU) of the spine (from C2 to S1) were scored for bone marrow edema. A single DVU has 18 scoring units, and each has score of 0 or 1, bringing the maximum total score to 414, the sum ranges from 0 to 414 with higher scores reflecting worse disease. Scoring was performed by central readers. LS mean was determined by ANCOVA with factors for treatment, geographic region, baseline CRP status, number of prior TNF inhibitors used and baseline value.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score)
Units on a scalePlacebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score)3.29 ± 1.402-2.99 ± 1.384-3.97 ± 1.534
Statistical analysis
  • Placebo vs 80 mg Q4W Ixekizumab · ANCOVA · p = 0.001 · Ls mean difference (final values): -6.29 · 95% CI -10.0 to -2.5
  • Placebo vs 80 mg Q2W Ixekizumab · ANCOVA · p = <0.001 · Ls mean difference (final values): -7.27 · 95% CI -11.2 to -3.4
SecondaryChange From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)

High sensitivity CRP is the measure of acute phase reactant. It was measured with a high sensitivity assay at the central laboratory to help assess the effect of ixekizumab on disease activity. High sensitivity CRP is a sensitive laboratory assay for serum levels of C-Reactive Protein, which is a biomarker of inflammation. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · milligram per liter (mg/L)
Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)
milligram per liter (mg/L)Placebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)9.719 ± 2.7383-11.096 ± 2.6190-8.121 ± 2.8829
Statistical analysis
  • Placebo vs 80 mg Q4W Ixekizumab · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -20.816 · 95% CI -28.187 to -13.444
  • Placebo vs 80 mg Q2W Ixekizumab · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -17.841 · 95% CI -25.518 to -10.163
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)

BASMI is a combined index comprising of 5 clinical measurements of spinal mobility in patients with radiographic axial spondyloarthritis (rad-axSpA). 1. Lateral Spinal Flexion 2. Tragus-to-wall distance 3. Lumbar Flexion (modified Schober) 4. Maximal intermalleolar distance and 5. Cervical rotation. The BASMI linear result is the average of the 5 assessments and ranges from 0 to 10. The higher the BASMI score the more severe the patient's limitation of movement due to their AS. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)
Units on a scalePlacebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)-0.046 ± 0.0939-0.349 ± 0.0897-0.217 ± 0.0981
Statistical analysis
  • Placebo vs 80 mg Q4W Ixekizumab · Mixed Models Analysis · p = 0.018 · Ls mean difference (final values): -0.304 · 95% CI -0.555 to -0.053
  • Placebo vs 80 mg Q2W Ixekizumab · Mixed Models Analysis · p = 0.194 · Ls mean difference (final values): -0.172 · 95% CI -0.431 to 0.088
SecondaryChange From Baseline in Chest Expansion

Chest expansion is the difference, in centimeter (cm), between the circumference of the chest in maximal inspiration and maximal expiration. While patients have their hands resting on or behind the head, the assessor will measure the chest encircled length by centimeter (cm) at the fourth intercostal level anteriorly. Two tries were recorded. The better measurement (larger difference) of 2 tries (in centimeters) was used for analyses. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · centimeter(cm)
Change From Baseline in Chest Expansion
centimeter(cm)Placebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Change From Baseline in Chest Expansion0.04 ± 0.6441.27 ± 0.6180.27 ± 0.655
Statistical analysis
  • Placebo vs 80 mg Q4W Ixekizumab · Mixed Models Analysis · p = 0.170 · Ls mean difference (final values): 1.23 · 95% CI -0.53 to 2.99
  • Placebo vs 80 mg Q2W Ixekizumab · Mixed Models Analysis · p = 0.800 · Ls mean difference (final values): 0.23 · 95% CI -1.57 to 2.04
SecondaryChange From Baseline in Occiput to Wall Distance

The participant is to make a maximum effort to touch the head against the wall when standing with heels and back against the wall (occiput). Then the distance from occiput to wall is measured. Two tries will be recorded. The better (smaller) measurement of 2 tries (in centimeters) will be used for analyses. LS mean was determined by MMRM with factors for treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · cm
Change From Baseline in Occiput to Wall Distance
cmPlacebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Change From Baseline in Occiput to Wall Distance0.35 ± 0.3840.03 ± 0.365-0.65 ± 0.399
Statistical analysis
  • Placebo vs 80 mg Q4W Ixekizumab · Mixed Models Analysis · p = 0.547 · Ls mean difference (final values): -0.31 · 95% CI -1.34 to 0.71
  • Placebo vs 80 mg Q2W Ixekizumab · Mixed Models Analysis · p = 0.064 · Ls mean difference (final values): -1.00 · 95% CI -2.06 to 0.06
SecondaryChange From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)

The MASES is an index used to measure the severity of enthesitis. The MASES assesses 13 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include costochondral 1 (right/left), costochondral 7 (right/left), spinal iliaca anterior superior (right/left), crista iliaca (right/left), spina iliaca posterior (right/left), processus spinosus L5, and Achilles tendon proximal insertion (right/left). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)
Units on a scalePlacebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)-1.9 ± 0.43-1.8 ± 0.40-2.2 ± 0.42
Statistical analysis
  • Placebo vs 80 mg Q4W Ixekizumab · Mixed Models Analysis · p = 0.861 · Ls mean difference (final values): 0.1 · 95% CI -1.0 to 1.3
  • Placebo vs 80 mg Q2W Ixekizumab · Mixed Models Analysis · p = 0.626 · Ls mean difference (final values): -0.3 · 95% CI -1.4 to 0.9
SecondaryChange From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Score

The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Score
Units on a scalePlacebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Score-1.9 ± 0.44-2.3 ± 0.40-1.8 ± 0.45
Statistical analysis
  • Placebo vs 80 mg Q4W Ixekizumab · Mixed Models Analysis · p = 0.504 · Ls mean difference (final values): -0.4 · 95% CI -1.6 to 0.8
  • Placebo vs 80 mg Q2W Ixekizumab · Mixed Models Analysis · p = 0.860 · Ls mean difference (final values): 0.1 · 95% CI -1.1 to 1.3
SecondaryChange From Baseline in Severity of Peripheral Arthritis by Tender Joint Count (TJC) Scores

The number of tender and painful joints was determined by examination of 46 joints (23 joints on each side of the body). The 46 joints were assessed and classified as tender or not tender. Sum of all joints checked to be tender/painful divided by number of evaluable joints which was multiplied by 46 to obtain TJC score. The scores ranges from 0 (no tender/painful joints) to 46 (all joints tender/painful). LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Tender Joint Count
Change From Baseline in Severity of Peripheral Arthritis by Tender Joint Count (TJC) Scores
Tender Joint CountPlacebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Change From Baseline in Severity of Peripheral Arthritis by Tender Joint Count (TJC) Scores-3.9 ± 0.79-4.8 ± 0.69-5.0 ± 0.79
Statistical analysis
  • Placebo vs 80 mg Q4W Ixekizumab · Mixed Models Analysis · p = 0.362 · Ls mean difference (final values): -0.9 · 95% CI -3.0 to 1.1
  • Placebo vs 80 mg Q2W Ixekizumab · Mixed Models Analysis · p = 0.303 · Ls mean difference (final values): -1.1 · 95% CI -3.3 to 1.0
SecondaryChange From Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC) Scores

The number of swollen joints was determined by examination of 44 joints (22 joints on each side of the body). The 44 joints were assessed and classified as swollen or not swollen. Sum of all joints checked to be swollen divided by number of evaluable joints which was multiplied by 44 to obtain SJC score. The SJC score ranges from 0 (no swollen joints) to 44 (all joints swollen). LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Swollen Joint Count
Change From Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC) Scores
Swollen Joint CountPlacebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Change From Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC) Scores-2.4 ± 0.51-2.6 ± 0.49-3.0 ± 0.54
Statistical analysis
  • Placebo vs 80 mg Q4W Ixekizumab · Mixed Models Analysis · p = 0.813 · Ls mean difference (final values): -0.2 · 95% CI -1.5 to 1.2
  • Placebo vs 80 mg Q2W Ixekizumab · Mixed Models Analysis · p = 0.410 · Ls mean difference (final values): -0.6 · 95% CI -2.0 to 0.8
SecondaryPercentage of Participants With Anterior Uveitis

Anterior uveitis is an inflammation of the middle layer of the eye. which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With Anterior Uveitis
Percentage of ParticipantsPlacebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Percentage of Participants With Anterior Uveitis01.83.1
SecondaryChange From Baseline in the Fatigue Numeric Rating Scale (NRS) Score

The fatigue severity NRS is a participant administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine". Participants rate their fatigue (feeling tired or worn out) by circling the 1 number that describes their worst level of fatigue during the previous 24 hours. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score
Units on a scalePlacebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score-0.7 ± 0.24-2.0 ± 0.23-1.7 ± 0.25
Statistical analysis
  • Placebo vs 80 mg Q4W Ixekizumab · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -1.2 · 95% CI -1.9 to -0.6
  • Placebo vs 80 mg Q2W Ixekizumab · Mixed Models Analysis · p = 0.005 · Ls mean difference (final values): -1.0 · 95% CI -1.6 to -0.3
SecondaryChange From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)

The Jenkins Sleep Evaluation Questionnaire (JSEQ) is a 4 item scale designed to estimate sleep problems in clinical research. The JSEQ assesses the frequency of sleep disturbance in 4 categories: 1) trouble falling asleep, 2) waking up several times during the night, 3) having trouble staying asleep (including waking up far too early), and 4) waking up after the usual amount of sleep feeling tired and worn out. Patients report the numbers of days they experience each of these problems in the past month on a 6 point Likert Scale ranging from 0 = "no days" to 5 = "22-30 days. The total JSEQ score ranges from 0 to 20, with higher scores indicating greater sleep disturbance. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)
Units on a scalePlacebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)-1.8 ± 0.50-3.0 ± 0.48-2.4 ± 0.52
Statistical analysis
  • Placebo vs 80 mg Q4W Ixekizumab · Mixed Models Analysis · p = 0.088 · Ls mean difference (final values): -1.2 · 95% CI -2.5 to 0.2
  • Placebo vs 80 mg Q2W Ixekizumab · Mixed Models Analysis · p = 0.366 · Ls mean difference (final values): -0.6 · 95% CI -2.0 to 0.7
SecondaryChange From Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores

The WPAI-SpA consists of 6 questions to determine employment status, hours missed from work because of SpA, hours missed from work for other reasons, hours actually worked, the degree to which SpA affected work productivity while at work, and the degree to which SpA affected activities outside of work. The WPAI-SpA has been validated in the rad-axSpA patient population. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. The computed percentage range for each sub-scale was from 0-100, with higher scores indicating greater impairment and less productivity. LS mean was determined by ANCOVA with treatment, geographic region, baseline CRP status, number of prior TNFi and baseline value as fixed factors.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores
Units on a scalePlacebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Overall Work Impairment Score-9.84 ± 3.733-20.97 ± 4.016-23.50 ± 4.225
Percentage of Activity Impairment-10.1 ± 2.60-16.5 ± 2.44-18.4 ± 2.74
Statistical analysis
  • Placebo vs 80 mg Q4W Ixekizumab · ANCOVA · p = 0.038 · Ls mean difference (final values): -11.13 · 95% CI -21.65 to -0.60
  • Placebo vs 80 mg Q2W Ixekizumab · ANCOVA · p = 0.012 · Ls mean difference (final values): -13.66 · 95% CI -24.23 to -3.10
  • Placebo vs 80 mg Q4W Ixekizumab · ANCOVA · p = 0.071 · Ls mean difference (final values): -6.3 · 95% CI -13.2 to 0.5
  • Placebo vs 80 mg Q2W Ixekizumab · ANCOVA · p = 0.024 · Ls mean difference (final values): -8.3 · 95% CI -15.5 to -1.1
SecondaryChange From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score

ASAS-NSAID score is used to present the NSAID intake by considering the type of NSAID, the total dose, \& the number of days taking NSAID during a period of interest (PI). For NSAID equivalent scoring system, range is from 0 to 100, higher the score greated the NSAID intake. ASAS-NSAID score= (equivalent NSAID score) x (days of intake during PI) x (days per week)/(PI in days).

Time frame:
Baseline, Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score
Units on a scalePBO/IXEIXE80Q4W/IXE80Q4WIXE80Q2W/IXE80Q2W
Change From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score-9.84 ± 34.435-5.52 ± 19.553-2.33 ± 24.019
SecondaryPercentage of Participants With Anti-Ixekizumab Antibodies

A treatment emergent - antidrug antibody (TE-ADA) positive patient is defined as: a) a patient with a \>= 4-fold increase over a positive baseline antibody titer; or b) for a negative baseline titer, a patient with an increase from the baseline to a level of \>= 1:10. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With Anti-Ixekizumab Antibodies
Percentage of ParticipantsPlacebo80 mg Q4W Ixekizumab80 mg Q2W Ixekizumab
Percentage of Participants With Anti-Ixekizumab Antibodies2.97.14.1
SecondaryPharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss)

Pharmacokinetics (PK): Steady-state trough serum concentration of Ixekizumab at week 16.

Time frame:
Week 16
Reported as:
Geometric mean · Microgram per milliliters (µg/mL)
Pharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss)
Microgram per milliliters (µg/mL)80 mg Q4W Ixekizumab (Starting Dose 80 mg)80 mg Q4W Ixekizumab (Starting Dose 160 mg)80 mg Q2W Ixekizumab (Starting Dose 80 mg)80 mg Q2W Ixekizumab (Starting Dose 160 mg)
Pharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss)2.10 ± 1062.47 ± 1016.27 ± 1588.52 ± 50

Adverse events

Collected over Up To 76 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
80 mg Q2W Ixekizumab-Blinded Treatment Period1/98 (1%)3/98 (3.1%)25/98 (25.5%)
80 mg Q4W Ixekizumab-Blinded Treatment Period0/114 (0%)4/114 (3.5%)25/114 (21.9%)
PBO-Blinded Treatment Period0/104 (0%)5/104 (4.8%)12/104 (11.5%)
IXE80Q2W/IXE80Q2W-Extended Treatment Period0/90 (0%)1/90 (1.1%)26/90 (28.9%)
IXE80Q4W/IXE80Q4W-Extended Treatment Period0/98 (0%)2/98 (2%)19/98 (19.4%)
PBO/IXE-Extended Treatment Period0/93 (0%)6/93 (6.5%)19/93 (20.4%)
IXE80Q2W-Follow-up Period0/22 (0%)1/22 (4.5%)1/22 (4.5%)
IXE80Q4W-Follow-up Period0/34 (0%)2/34 (5.9%)3/34 (8.8%)
PBO-Follow-up Period0/5 (0%)0/5 (0%)1/5 (20%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
Event80 mg Q2W Ixekizumab-Blinded Treatment Period80 mg Q4W Ixekizumab-Blinded Treatment PeriodPBO-Blinded Treatment PeriodIXE80Q2W/IXE80Q2W-Extended Treatment PeriodIXE80Q4W/IXE80Q4W-Extended Treatment PeriodPBO/IXE-Extended Treatment PeriodIXE80Q2W-Follow-up PeriodIXE80Q4W-Follow-up PeriodPBO-Follow-up Period
Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/980/1140/1040/900/980/931/220/340/5
Acute promyelocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/980/1140/1040/900/980/930/221/340/5
Loss of consciousnessNervous system disorders0/980/1140/1040/900/980/930/221/340/5
SyncopeNervous system disorders0/980/1140/1040/900/980/930/221/340/5
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/980/1140/1040/900/980/930/221/340/5
GastroenteritisInfections and infestations0/980/1140/1041/900/980/930/220/340/5
Acute myocardial infarctionCardiac disorders0/980/1140/1040/900/981/930/220/340/5
BradycardiaCardiac disorders0/980/1140/1040/901/981/930/220/340/5
Inguinal herniaGastrointestinal disorders0/980/1141/1040/900/981/930/220/340/5
PneumoniaInfections and infestations0/980/1140/1040/900/981/930/220/340/5
Most frequent other events
Showing 10 of 11
Most frequent other events
Event80 mg Q2W Ixekizumab-Blinded Treatment Period80 mg Q4W Ixekizumab-Blinded Treatment PeriodPBO-Blinded Treatment PeriodIXE80Q2W/IXE80Q2W-Extended Treatment PeriodIXE80Q4W/IXE80Q4W-Extended Treatment PeriodPBO/IXE-Extended Treatment PeriodIXE80Q2W-Follow-up PeriodIXE80Q4W-Follow-up PeriodPBO-Follow-up Period
Blood triglycerides increasedInvestigations0/980/1141/1041/900/981/930/220/341/5
Upper respiratory tract infectionInfections and infestations4/989/1143/1048/904/985/930/220/340/5
Injection site reactionGeneral disorders8/983/1141/1045/902/983/930/220/340/5
Vulvovaginal candidiasisInfections and infestations0/230/230/170/220/171/160/40/90/1
ArthralgiaMusculoskeletal and connective tissue disorders3/987/1144/1042/904/984/931/221/340/5
Back painMusculoskeletal and connective tissue disorders3/981/1142/1045/906/980/930/220/340/5
NasopharyngitisInfections and infestations4/985/1142/1044/903/983/930/222/340/5
Vulvovaginal burning sensationReproductive system and breast disorders0/230/230/170/221/170/160/40/90/1
Vulvovaginal drynessReproductive system and breast disorders0/230/230/170/221/170/160/40/90/1
Urinary tract infectionInfections and infestations2/980/1140/1045/902/982/930/220/340/5

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(Years)PBO/IXEIXE80Q4W/IXE80Q4WIXE80Q2W/IXE80Q2WTotal
Mean46.6 ± 12.7247.4 ± 13.3644.2 ± 10.7946.1 ± 12.43
Sex: Female, Male
Sex: Female, Male(Participants)PBO/IXEIXE80Q4W/IXE80Q4WIXE80Q2W/IXE80Q2WTotal
Female17232363
Male879175253
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PBO/IXEIXE80Q4W/IXE80Q4WIXE80Q2W/IXE80Q2WTotal
Hispanic or Latino333235100
Not Hispanic or Latino637053186
Unknown or Not Reported8121030
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PBO/IXEIXE80Q4W/IXE80Q4WIXE80Q2W/IXE80Q2WTotal
American Indian or Alaska Native44412
Asian13141340
Native Hawaiian or Other Pacific Islander0000
Black or African American1225
White859178254
More than one race1214
Unknown or Not Reported0101
Region of Enrollment
Region of Enrollment(Participants)PBO/IXEIXE80Q4W/IXE80Q4WIXE80Q2W/IXE80Q2WTotal
Puerto Rico1247
Argentina67518
United States14141240
United Kingdom96520
Spain37414
Canada1506
South Korea12111134
Netherlands1203
Finland0325
Brazil1081028
Poland22242066
Italy0112
Mexico13131339
Israel55616
France75517
Germany0101
08

Study locations

99 sites
  • Arizona Arthritis Research, PLC
    Phoenix, Arizona 85032, United States
  • Rheumatology Center of San Diego
    Escondido, California 92025, United States
  • Care Access Research - Huntington Beach
    Huntington Beach, California 92648, United States
  • Desert Medical Advances
    Palm Desert, California 92260, United States
  • Arthritis Assoc. & Osteoporosis Ctr of Colorado Springs, LLC
    Colorado Springs, Colorado 80920, United States
  • Denver Arthritis Center
    Denver, Colorado 80230, United States
  • Clinical Research Center of CT/NY
    Danbury, Connecticut 06810, United States
  • Arthritis Rheumatic Disease Specialties
    Aventura, Florida 33180, United States
  • Sarasota Arthritis Center
    Sarasota, Florida 34239, United States
  • Marietta Rheumatology
    Marietta, Georgia 30060, United States
  • St Luke's Clinic - Intermountain Orthopaedics
    Boise, Idaho 83702, United States
  • Institute of Arthritis Research
    Idaho Falls, Idaho 83404, United States
  • Center for Arthritis & Osteoporosis
    Elizabethtown, Kentucky 42701, United States
  • Klein and Associates MD, PA
    Cumberland, Maryland 21502, United States
  • Osteoporosis And Clinical Trial Center
    Hagerstown, Maryland 21740, United States
  • Arthritis Consultants
    Saint Louis, Missouri 63141, United States
  • The Center for Rheumatology
    Albany, New York 12203, United States
  • Shanahan Rheumatology & Immunotherapy
    Raleigh, North Carolina 27617, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Articularis Healthcare Group, INC dba Columbia Arthritis Ctr
    Columbia, South Carolina 29204, United States
  • Low Country Research Center
    North Charleston, South Carolina 29406, United States
  • Univ of Texas Health Science Center - Houston
    Houston, Texas 77030, United States
  • Southwest Rheumatology, P.A.
    Mesquite, Texas 75150, United States
  • Center for Arthritis and Rheumatic Diseases, PC
    Chesapeake, Virginia 23320, United States
  • Arthritis Northwest Rheumatology
    Spokane, Washington 99204, United States
  • Rheumatology and Immunotherapy Center
    Franklin, Wisconsin 53132, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rosario, S2000CFJ, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rosario, S2000DEJ, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Miguel de Tucuman, T4000AXL, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Miguel de Tucuman, T4000BRD, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Curitiba, 80440-080, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Goiás, 74043-110, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Juiz de Fora, 36010-570, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Porto Alegre, 90480-000, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sao Paulo, 01244-030, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    St. John's, A1C 5B8, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Trois-Rivieres, G8Z 1Y2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Victoria, V8V 3M9, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Helsinki, 00029, Finland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hyvinkaa, 05800, Finland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oulu, 90029, Finland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Clermont, 63003, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Le Kremlin Bicetre, 94270, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montpellier, 34295, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orleans, 45100, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paris CEDEX 14, 75679, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tours, 37044, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Berlin, 10117, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ashkelon, 7830604, Israel
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Haifa, 3525408, Israel
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Petach Tikva, 4941492, Israel
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tel Aviv, 6423906, Israel
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Milano, 20157, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Reggio Emilia, 42123, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Roma, 00168, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Siena, 53100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hyogo, 663-8501, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yamagata, 990-9585, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Daejeon, 35015, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 02447, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 03080, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 04763, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 05030, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 05278, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 05505, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 06273, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 06591, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 07061, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chihuahua, 31000, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guadalajara, 44650, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Merida, 97070, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexicali, 21200, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Monterrey, 64020, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Luis Potosi, 78213, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Amsterdam, 1105 AZ, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sneek, 8601 ZK, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bydgoszcz, 85-168, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Elblag, 82-300, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lodz, 90-558, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Poznan, 61-397, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Swidnik, 21-040, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warsaw, 01-518, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warszawa, 02-691, Poland
  • Office: Perez-De Jesus, Amarilis
    Caguas, 00725, Puerto Rico
  • GCM Medical Group PSC
    San Juan, 00909, Puerto Rico
  • Mindful Medical Research
    San Juan, 00918, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santurce, 00909, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cordoba, 14004, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Elche, 03202, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28007, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sabadell, 08208, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sevilla, 41010, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Basingstoke, RG24 9NA, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Norwich, NR4 7UY, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Solihull, B91 3JL, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stoke on Trent, ST6 7AG, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wolverhampton, WV10 0QP, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wythenshawe, M23 9LT, United Kingdom
09

References and documents

Publications

  • van der Horst-Bruinsma IE, de Vlam K, Walsh JA, Bolce R, Hunter T, Sandoval D, Zhu D, Geneus V, Soriano ER, Magrey M. Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials. Adv Ther. 2022 Jun;39(6):2806-2819. doi: 10.1007/s12325-022-02132-2. Epub 2022 Apr 16. PubMed 35429281 ↗
  • Maksymowych WP, Bolce R, Gallo G, Seem E, Geneus VJ, Sandoval DM, Ostergaard M, Tada K, Baraliakos X, Deodhar A, Gensler LS. Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging. Rheumatology (Oxford). 2022 Nov 2;61(11):4324-4334. doi: 10.1093/rheumatology/keac104. PubMed 35188180 ↗
  • van der Heijde D, Ostergaard M, Reveille JD, Baraliakos X, Kronbergs A, Sandoval DM, Li X, Carlier H, Adams DH, Maksymowych WP. Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years. J Rheumatol. 2022 Mar;49(3):265-273. doi: 10.3899/jrheum.210471. Epub 2021 Dec 1. PubMed 34853086 ↗
  • Deodhar AA, Mease PJ, Rahman P, Navarro-Compan V, Strand V, Hunter T, Bolce R, Leon L, Lauzon S, Marzo-Ortega H. Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results. BMC Rheumatol. 2021 Sep 20;5(1):35. doi: 10.1186/s41927-021-00205-3. PubMed 34538257 ↗
  • Dougados M, Wei JC, Landewe R, Sieper J, Baraliakos X, Van den Bosch F, Maksymowych WP, Ermann J, Walsh JA, Tomita T, Deodhar A, van der Heijde D, Li X, Zhao F, Bertram CC, Gallo G, Carlier H, Gensler LS; COAST-V and COAST-W Study Groups. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2020 Feb;79(2):176-185. doi: 10.1136/annrheumdis-2019-216118. Epub 2019 Nov 4. Erratum In: Ann Rheum Dis. 2020 Jun;79(6):e75. doi: 10.1136/annrheumdis-2019-216118corr1. PubMed 31685553 ↗
  • Mease P, Walsh JA, Baraliakos X, Inman R, de Vlam K, Wei JC, Hunter T, Gallo G, Sandoval D, Zhao F, Dong Y, Bolce R, Marzo-Ortega H. Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis. Rheumatol Ther. 2019 Sep;6(3):435-450. doi: 10.1007/s40744-019-0165-3. Epub 2019 Jun 28. PubMed 31254223 ↗
  • Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, Jarvinen P, Sanchez-Burson J, Gaffney K, Lee EB, Krishnan E, Santisteban S, Li X, Zhao F, Carlier H, Reveille JD; COAST-W Study Group. Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol. 2019 Apr;71(4):599-611. doi: 10.1002/art.40753. Epub 2019 Mar 8. PubMed 30343531 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in May 2018, 25 months.

Results were first posted in Oct 2019, 1 year 5 months after primary completion. A results delay was requested in Jun 2018.

Of 12 phase 3 interventional studies under Spondylarthritis, half reached primary completion within 21 months of starting (the median); a quarter within 15 and three quarters within 37. This study's 25 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2016
First posted
Mar 2, 2016
StartActual
Apr 12, 2016
Primary completionActual
May 18, 2018
CompletionActual
May 3, 2019
Results delay requested
Jun 5, 2018
Results first posted
Oct 30, 2019
Last update
Jun 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02696798
Responsible party
Sponsor
First posted
Mar 2, 2016
Start date
Apr 12, 2016
Primary completion
May 18, 2018
Completion
May 3, 2019
Results posted
Oct 30, 2019
Last update
Jun 17, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion